1Department of Neurosurgery.
2Institute of Neurology.
J Neurosurg. 2018 Aug;129(2):341-353. doi: 10.3171/2017.4.JNS162991. Epub 2017 Oct 27.
OBJECTIVE Glioblastoma (GBM) is characterized by distinct intratumoral histopathological heterogeneity with regard to variable tumor morphology, cell proliferation, and microvascularity. Maximum resection of a GBM results in an improved prognosis and thus represents the aim of surgery in the majority of cases. Fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) is currently widely applied for improved intraoperative tumor visualization in patients with a GBM. Three intratumoral fluorescence levels (i.e., strong, vague, or no fluorescence) can usually be distinguished during surgery. So far, however, their exact histopathological correlates and their surgical relevance have not been clarified sufficiently. Thus, the aim of this study was to systematically analyze tissue samples from newly diagnosed GBMs with different fluorescence levels according to relevant histopathological parameters. METHODS This prospective study recruited patients who underwent 5-ALA fluorescence-guided resection of a newly diagnosed radiologically suspected GBM. Each patient received 5-ALA approximately 3 hours before surgery, and a modified neurosurgical microscope was applied for intraoperative visualization of 5-ALA-induced fluorescence. During surgery, tissue samples with strong, vague, or no fluorescence were collected. For each sample, the presence of tumor tissue, quality of tissue (compact, infiltrative, or no tumor), histopathological criteria of malignancy (cell density, nuclear pleomorphism, mitotic activity, and presence of microvascular proliferation/necrosis), proliferation rate (MIB-1 labeling index [LI]), and microvessel density (using CD34 staining) were investigated. RESULTS Altogether, 77 patients with a newly diagnosed, histopathologically confirmed GBM were included, and 131 samples with strong fluorescence, 69 samples with vague fluorescence, and 67 samples with no fluorescence were collected. Tumor tissue was detected in all 131 (100%) of the samples with strong fluorescence and in 65 (94%) of the 69 samples with vague fluorescence. However, mostly infiltrative tumor tissue was still found in 33 (49%) of 67 samples despite their lack of fluorescence. Strong fluorescence corresponded to compact tumors in 109 (83%) of 131 samples, whereas vague fluorescence was consistent with infiltrative tumors in 44 (64%) of 69 samples. In terms of the histopathological criteria of malignancy, a significant positive correlation of all analyzed parameters comprising cell density, nuclear pleomorphism, mitotic activity, microvascular proliferation, and necrosis with the 3 fluorescence levels was observed (p < 0.001). Furthermore, the proliferation rate significantly and positively correlated with strong (MIB-1 LI 28.3%), vague (MIB-1 LI 16.7%), and no (MIB-1 LI 8.8%) fluorescence (p < 0.001). Last, a significantly higher microvessel density was detected in samples with strong fluorescence (CD34 125.5 vessels/0.25 mm) than in those with vague (CD34 82.8 vessels/0.25 mm) or no (CD34 68.6 vessels/0.25 mm) fluorescence (p < 0.001). CONCLUSIONS Strong and vague 5-ALA-induced fluorescence enables visualization of intratumoral areas with specific histopathological features and thus supports neurosurgeons in improving the extent of resection in patients with a newly diagnosed GBM. Despite the lack of fluorescence, tumor tissue was still observed in approximately half of the cases. To overcome this current limitation, the promising approach of complementary spectroscopic measurement of fluorescence should be investigated further.
目的
胶质母细胞瘤(GBM)的特征是肿瘤形态、细胞增殖和微血管性存在明显的肿瘤内组织病理学异质性。最大限度地切除 GBM 可改善预后,因此在大多数情况下代表了手术的目标。目前,使用 5-氨基酮戊酸(5-ALA)的荧光引导手术广泛应用于提高 GBM 患者术中肿瘤可视化。在手术过程中通常可以区分三种肿瘤内荧光水平(即强、模糊或无荧光)。然而,到目前为止,它们的确切组织病理学相关性及其手术相关性尚未得到充分阐明。因此,本研究的目的是根据相关组织病理学参数系统地分析不同荧光水平的新诊断 GBM 组织样本。
方法
这项前瞻性研究招募了接受新诊断的影像学可疑 GBM 5-ALA 荧光引导切除术的患者。每位患者在手术前大约 3 小时接受 5-ALA,术中应用改良神经外科显微镜观察 5-ALA 诱导的荧光。在手术过程中,收集具有强、模糊或无荧光的组织样本。对于每个样本,存在肿瘤组织、组织质量(致密、浸润性或无肿瘤)、恶性组织病理学标准(细胞密度、核异型性、有丝分裂活性和微血管增生/坏死的存在)、增殖率(MIB-1 标记指数 [LI])和微血管密度(使用 CD34 染色)。
结果
共纳入 77 例新诊断的、经组织病理学证实的 GBM 患者,共采集 131 份强荧光样本、69 份模糊荧光样本和 67 份无荧光样本。在 131 份强荧光样本(100%)和 69 份模糊荧光样本(94%)中均检测到肿瘤组织。然而,尽管缺乏荧光,在 67 份样本(49%)中仍发现主要是浸润性肿瘤组织。强荧光与 109 份样本中的致密肿瘤(83%)相对应,而模糊荧光与 69 份样本中的浸润性肿瘤相对应(64%)。在恶性组织病理学标准方面,观察到所有分析参数(细胞密度、核异型性、有丝分裂活性、微血管增生和坏死)与 3 种荧光水平之间存在显著正相关(p<0.001)。此外,增殖率与强(MIB-1 LI 28.3%)、模糊(MIB-1 LI 16.7%)和无(MIB-1 LI 8.8%)荧光均呈显著正相关(p<0.001)。最后,强荧光样本中的微血管密度(CD34 125.5 个血管/0.25 mm)明显高于模糊荧光样本(CD34 82.8 个血管/0.25 mm)或无荧光样本(CD34 68.6 个血管/0.25 mm)(p<0.001)。
结论
强荧光和模糊荧光能够可视化肿瘤内具有特定组织病理学特征的区域,从而支持神经外科医生改善新诊断 GBM 患者的切除范围。尽管缺乏荧光,但在大约一半的病例中仍观察到肿瘤组织。为了克服这一当前局限性,应进一步研究有前途的荧光互补光谱测量方法。